Erratum: New aminoimidazoles as β-secretase (BACE-1) inhibitors showing amyloid-β (Aβ) lowering in brain (Journal of Medicinal Chemistry (2012) 55 (9297-9311) DOI: 10.1021/jm300991n);New aminoimidazoles as β-secretase (BACE-1) inhibitors showing amyloid-β (aβ) lowering in brain

Journal of Medicinal Chemistry

Volumn 55, Issue 21, 2012, Pages 9297-9311

  Gravenfors, Ylva ^a   Viklund, Jenny ^a   Blid, Jan ^a   Ginman, Tobias ^a   Karlström, Sofia ^a   Kihlström, Jacob ^a   Kolmodin, Karin ^a   Lindström, Johan ^a   Von Berg, Stefan ^a   Von Kieseritzky, Fredrik ^a   Slivo, Can ^a   Swahn, Britt Marie ^a   Olsson, Lise Lotte ^b   Johansson, Patrik ^b   Eketjäll, Susanna ^a   Fälting, Johanna ^a   Jeppsson, Fredrik ^a   Strömberg, Kia ^a   Janson, Juliette ^a   Rahm, Fredrik ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 METHOXY 3,5 DIMETHYLPHENYL) 5 METHYL 2 [3 (PYRIMIDIN 5 YL)PHENYL] 2H IMIDAZOL 4 AMINE; AMINO 2H IMIDAZOLE DERIVATIVE; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BETA SECRETASE 1; BETA SECRETASE INHIBITOR; IMIDAZOLE DERIVATIVE; POTASSIUM CHANNEL HERG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG PENETRATION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; FEMALE; GUINEA PIG; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

EID: 84868543653     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301629c     Document Type: Erratum

References (62)

1. Querfurth, H. W.; LaFerla, F. M. Alzheimers disease N. Engl. J. Med. 2010, 362, 329-344
2. 2012 Alzheimers disease facts and figures. Alzheimer's Dementia 2012, 8, 131-168.
3. Hardy, J.; Allsop, D. Amyloid deposition as the central event in the etiology of Alzheimers disease Trends Pharmacol. Sci. 1991, 12, 383-388
4. Lee, V. M.; Goedert, M.; Trojanowski, J. Q. Neurodegenerative tauopathies Annu. Rev. Neurosci. 2001, 24, 1121-1159
5. Hardy, J.; Selkoe, D. J. The amyloid hypothesis of Alzheimers disease: progress and problems on the road to therapeutics Science (Washington, DC, U. S.) 2002, 297, 353-356
6. Hussain, I.; Powell, D.; Howlett, D. R.; Tew, D. G.; Meek, T. D.; Chapman, C.; Gloger, I. S.; Murphy, K. E.; Southan, C. D.; Ryan, D. M.; Smith, T. S.; Simmons, D. L.; Walsh, F. S.; Dingwall, C.; Christie, G. Identification of a novel aspartic protease (Asp 2) as β-secretase Mol. Cell. Neurosci. 1999, 14, 419-427
7. Sinha, S.; Anderson, J. P.; Barbour, R.; Basi, G. S.; Caccavello, R.; Davis, D.; Doan, M.; Dovey, H. F.; Frigon, N.; Hong, J.; Jacobson-Croak, K.; Jewett, N.; Keim, P.; Knops, J.; Lieberburg, I.; Power, M.; Tan, H.; Tatsuno, G.; Tung, J.; Schenk, D.; Seubert, P.; Suomensaari, S. M.; Wang, S.; Walker, D.; Zhao, J.; McConlogue, L.; John, V. Purification and cloning of amyloid precursor protein β-secretase from human brain Nature (London) 1999, 402, 537-540
8. Vassar, R.; Bennett, B. D.; Babu-Khan, S.; Kahn, S.; Mendiaz, E. A.; Denis, P.; Teplow, D. B.; Ross, S.; Amarante, P.; Loeloff, R.; Luo, Y.; Fisher, S.; Fuller, J.; Edenson, S.; Lile, J.; Jarosinski, M. A.; Biere, A. L.; Curran, E.; Burgess, T.; Louis, J.; Collins, F.; Treanor, J.; Rogers, G.; Citron, M. β-Secretase cleavage of Alzheimers amyloid precursor protein by the transmembrane aspartic protease BACE Science (Washington, DC, U. S.) 1999, 286, 735-741
9. Yan, R.; Bienkowski, M. J.; Shuck, M. E.; Miao, H.; Tory, M. C.; Pauley, A. M.; Brashler, J. R.; Stratman, N. C.; Mathews, W. R.; Buhl, A. E.; Carter, D. B.; Tomasselli, A. G.; Parodi, L. A.; Heinrikson, R. L.; Gurney, M. E. Membrane-anchored aspartyl protease with Alzheimers disease β-secretase activity Nature (London) 1999, 402, 533-537
10. Lin, X.; Koelsch, G.; Wu, S.; Downs, D.; Dashti, A.; Tang, J. Human aspartic protease memapsin 2 cleaves the β-secretase site of β-amyloid precursor protein Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 1456-1460
11. Price, D. L.; Sisodia, S. S. Mutant genes in familial Alzheimers disease and transgenic models Annu. Rev. Neurosci. 1998, 21, 479-505
12. Hardy, J. A.; Higgins, G. A. Alzheimers disease: the amyloid cascade hypothesis Science (Washington, DC, U. S.) 1992, 256, 184-185
13. Albert, J. S. Progress in the development of β-secretase inhibitors for Alzheimers disease Prog. Med. Chem. 2009, 48, 133-161
14. Evin, G.; Lessene, G.; Wilkins, S. BACE inhibitors as potential drugs for the treatment of Alzheimers disease: focus on bioactivity Recent Pat. CNS Drug Discovery 2011, 6, 91-106
15. Probst, G.; Xu, Y. Small-molecule BACE1 inhibitors: a patent literature review (2006-2011) Expert Opin. Ther. Pat. 2012, 22, 511-540
16. Ghosh, A. K.; Shin, D.; Downs, D.; Koelsch, G.; Lin, X.; Ermolieff, J.; Tang, J. Design of potent inhibitors for human brain memapsin 2 (β-secretase) J. Am. Chem. Soc. 2000, 122, 3522-3523
17. Cumming, J. N.; Iserloh, U.; Kennedy, M. E. Design and development of BACE-1 inhibitors Curr. Opin. Drug Discovery Dev. 2004, 7, 536-556
18. Malamas, M. S.; Erdei, J.; Gunawan, I.; Turner, J.; Hu, Y.; Wagner, E.; Fan, K.; Chopra, R.; Olland, A.; Bard, J.; Jacobsen, S.; Magolda, R. L.; Pangalos, M.; Robichaud, A. J. Design and synthesis of 5,5′-disubstituted aminohydantoins as potent and selective human β-secretase (BACE1) inhibitors J. Med. Chem. 2010, 53, 1146-1158
19. Swahn, B.; Holenz, J.; Kihlstrom, J.; Kolmodin, K.; Lindstrom, J.; Plobeck, N.; Rotticci, D.; Sehgelmeble, F.; Sundstrom, M.; Berg, S. v.; Falting, J.; Georgievska, B.; Gustavsson, S.; Neelissen, J.; Ek, M.; Olsson, L.; Berg, S. Aminoimidazoles as BACE-1 inhibitors: the challenge to achieve in vivo brain efficacy Bioorg. Med. Chem. Lett. 2012, 22, 1854-1859
20. May, P. C.; Dean, R. A.; Lowe, S. L.; Martenyi, F.; Sheehan, S. M.; Boggs, L. N.; Monk, S. A.; Mathes, B. M.; Mergott, D. J.; Watson, B. M.; Stout, S. L.; Timm, D. E.; LaBell, E. S.; Gonzales, C. R.; Nakano, M.; Jhee, S. S.; Yen, M.; Ereshefsky, L.; Lindstrom, T. D.; Calligaro, D. O.; Cocke, P. J.; Hall, D. G.; Friedrich, S.; Citron, M.; Audia, J. E. Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor J. Neurosci. 2011, 31, 16507-16516
21. Tresadern, G.; Delgado, F.; Delgado, O.; Gijsen, H.; Macdonald, G. J.; Moechars, D.; Rombouts, F.; Alexander, R.; Spurlino, J.; Van Gool, M.; Vega, J. A.; Trabanco, A. A. Rational design and synthesis of aminopiperazinones as beta-secretase (BACE) inhibitors Bioorg. Med. Chem. Lett. 2011, 21, 7255-7260
22. Swahn, B.; Kolmodin, K.; Karlström, S.; von Berg, S.; Söderman, P.; Holenz, J.; Berg, S.; Lindström, J.; Sundström, M.; Turek, D.; Kihlström, J.; Slivo, C.; Andersson, L.; Pyring, D.; Rotticci, D.; Öhberg, L.; Kers, A.; Bogar, K.; Bergh, M.; Olsson, L.; Janson, J.; Eketjäll, S.; Georgievska, B.; Jeppsson, F.; Fälting, J. Design and synthesis of β-secretase (bace1) inhibitors with in vivo brain reduction of β-amyloid peptides. J. Med. Chem. [Online early access]. DOI: 10.1021/jm3009025. Published Online: Aug 27, 2012.
23. Cumming, J. N.; Smith, E. M.; Wang, L.; Misiaszek, J.; Durkin, J.; Pan, J.; Iserloh, U.; Wu, Y.; Zhu, Z.; Strickland, C.; Voigt, J.; Chen, X.; Kennedy, M. E.; Kuvelkar, R.; Hyde, L. A.; Cox, K.; Favreau, L.; Czarniecki, M. F.; Greenlee, W. J.; McKittrick, B. A.; Parker, E. M.; Stamford, A. W. Structure based design of iminohydantoin BACE1 inhibitors: identification of an orally available, centrally active BACE1 inhibitor Bioorg. Med. Chem. Lett. 2012, 22, 2444-2449
24. Weiss, M. M.; Williamson, T.; Babu-Khan, S.; Bartberger, M. D.; Brown, J.; Chen, K.; Cheng, Y.; Citron, M.; Croghan, M. D.; Dineen, T. A.; Esmay, J.; Graceffa, R. F.; Harried, S.; Hickman, D.; Hitchcock, S. A.; Horne, D. B.; Huang, H.; Imbeah-Ampiah, R.; Judd, T.; Kaller, M. R.; Kreiman, C. R.; La, D. S.; Li, V.; Lopez, P.; Louie, S.; Monenschein, H.; Nguyen, T. T.; Pennington, L. D.; Rattan, C.; San, M. T.; Sickmier, E. A.; Wahl, R. C.; Wen, P. H.; Wood, S.; Xue, Q.; Yang, B. H.; Patel, V. F.; Zhong, W. Design and preparation of a potent series of hydroxyethylamine containing beta-secretase inhibitors that demonstrate robust reduction of central ss-amyloid J. Med. Chem. 2012, 55, 6243-6644
25. Rueeger, H.; Lueoend, R.; Rogel, O.; Rondeau, J.; Mobitz, H.; Machauer, R.; Jacobson, L.; Staufenbiel, M.; Desrayaud, S.; Neumann, U. Discovery of cyclic sulfone hydroxyethylamines as potent and selective β-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure-based design and in vivo reduction of amyloid β-peptides J. Med. Chem. 2012, 55, 3364-3386
26. Chang, W. P.; Huang, X.; Downs, D.; Cirrito, J. R.; Koelsch, G.; Holtzman, D. M.; Ghosh, A. K.; Tang, J. Beta-secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice FASEB J. 2011, 25, 775-784
27. Edwards, P. D.; Albert, J. S.; Sylvester, M.; Aharony, D.; Andisik, D.; Callaghan, O.; Campbell, J. B.; Carr, R. A.; Chessari, G.; Congreve, M.; Frederickson, M.; Folmer, R. H. A.; Geschwindner, S.; Koether, G.; Kolmodin, K.; Krumrine, J.; Mauger, R. C.; Murray, C. W.; Olsson, L.; Patel, S.; Spear, N.; Tian, G. Application of fragment-based lead generation to the discovery of novel, cyclic amidine β-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency J. Med. Chem. 2007, 50, 5912-5925
28. White, R.; Amegadzie, A.; Bryan, M. C.; Chen, J. J.; Cheng, A. C.; Dineen, T.; Epstein, O.; Gore, V. K.; Hua, Z.; Human, J. B.; Huang, H.; Kreiman, C.; La, D.; Liu, Q.; Ma, V. V.; Marx, I.; Patel, V. F.; Qian, W.; Weiss, M.; Yuan, C. C. WO2010030954A1, 2010.
29. Takahashi, H.; Fukumoto, H.; Maeda, R.; Terauchi, J.; Kato, K.; Miyamoto, M. Ameliorative effects of a non-competitive BACE1 inhibitor TAK-070 on Aβ peptide levels and impaired learning behavior in aged rats Brain Res. 2010, 1361, 146-156
30. Fukumoto, H.; Takahashi, H.; Tarui, N.; Matsui, J.; Tomita, T.; Hirode, M.; Sagayama, M.; Maeda, R.; Kawamoto, M.; Hirai, K.; Terauchi, J.; Sakura, Y.; Kakihana, M.; Kato, K.; Iwatsubo, T.; Miyamoto, M. A noncompetitive BACE1 inhibitor TAK-070 ameliorates Aβ pathology and behavioral deficits in a mouse model of Alzheimers disease J. Neurosci. 2010, 30, 11157-11166
31. Malamas, M. S.; Robichaud, A.; Erdei, J.; Quagliato, D.; Solvibile, W.; Zhou, P.; Morris, K.; Turner, J.; Wagner, E.; Fan, K.; Olland, A.; Jacobsen, S.; Reinhart, P.; Riddell, D.; Pangalos, M. Design and synthesis of aminohydantoins as potent and selective human β-secretase (BACE1) inhibitors with enhanced brain permeability Bioorg. Med. Chem. Lett. 2010, 20, 6597-6605
32. Roden, D. M. Drug-induced prolongation of the QT interval N. Engl. J. Med. 2004, 350, 1013-1022
33. Ekins, S.; Crumb, W. J.; Sarazan, R. D.; Wikel, J. H.; Wrighton, S. A. Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel J. Pharmacol. Exp. Ther. 2002, 301, 427-434
34. Diller, J. D. In silico hERG modelling: challenges and progress Curr. Comput.-Aided Drug Des. 2009, 5, 106-121
35. Asinger, F.; Schaefer, W.; Baumgarte, G.; Mueting, P. F. Concomitant action of elementary sulfur and gaseous ammonia on ketones. XXXVI. Action of sulfur and ammonia on acetophenone. II. Synthesis of 3-imidazoline-5-thiones Ann. 1963, 661, 95-110
36. Asinger, F.; Saus, A.; Offermanns, H.; Hahn, H. D. Concomitant action of elementary sulfur and gaseous ammonia on ketones. LII. Synthesis of α-oxo thio amides and substituted 3-imidazoline-5-thiones Justus Liebigs Ann. Chem. 1966, 691, 92-108
37. Asinger, F.; Schaefer, W.; Haaf, F. Concomitant action of elementary sulfur and gaseous ammonia on ketones. XXXVIII. Action of sulfur and ammonia on acetophenone. 3. Proof of structure and reactions of δ-3-imidazoline-5- thiones Justus Liebigs Ann. Chem. 1964, 672, 134-155
38. Blid, J.; Ginman, T.; Gravenfors, Y.; Karlstroem, S.; Kihlstroem, J.; Kolmodin, K.; Lindstroem, J.; Rahm, F.; Sundstroem, M.; Swahn, B.; Viklund, J.; von Berg, S.; von Kieseritzky, F. WO 2011/002408 A1, 2011.
39. Blid, J.; Ginman, T.; Gravenfors, Y.; Karlstroem, S.; Kolmodin, K.; Lindstroem, J.; Plobeck, N.; Rahm, F.; Swahn, B.; Viklund, J.; von Berg, S.; von Kieseritzky, D. WO 2011/002407 A1, 2011.
40. Lombardo, F.; Shalaeva, M. Y.; Tupper, K. A.; Gao, F. ElogDoct: a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds J. Med. Chem. 2001, 44, 2490-2497
41. Bridgland-Taylor, M. H.; Hargreaves, A. C.; Easter, A.; Orme, A.; Henthorn, D. C.; Ding, M.; Davis, A. M.; Small, B. G.; Heapy, C. G.; Abi-Gerges, N.; Persson, F.; Jacobson, I.; Sullivan, M.; Albertson, N.; Hammond, T. G.; Sullivan, E.; Valentin, J. P.; Pollard, C. E. Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT J. Pharmacol. Toxicol. Methods 2006, 54, 189-199
42. a values of pharmaceuticals by pressure-assisted capillary electrophoresis combined with short-end injection J. Chromatogr., A 2002, 979, 369-377
43. a values of pharmaceuticals by pressure-assisted capillary electrophoresis and mass spectrometry Rapid Commun. Mass Spectrom. 2003, 17, 2639-2648
44. Alelyunas, Y. W.; Liu, R.; Pelosi-Kilby, L.; Shen, C. Application of a dried-DMSO rapid throughput 24-h equilibrium solubility in advancing discovery candidates Eur. J. Pharm. Sci. 2009, 37, 172-182
45. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection Drug Discovery Today 2004, 9, 430-431
46. Stachel, S. J.; Coburn, C. A.; Rush, D.; Jones, K. L. G.; Zhu, H.; Rajapakse, H.; Graham, S. L.; Simon, A.; Katharine, H., M.; Allison, T. J.; Munshi, S. K.; Espeseth, A. S.; Zuck, P.; Colussi, D.; Wolfe, A.; Pietrak, B. L.; Lai, M.; Vacca, J. P. Discovery of aminoheterocycles as a novel β-secretase inhibitor class: pH dependence on binding activity part 1 Bioorg. Med. Chem. Lett. 2009, 19, 2977-2980
47. Waring, M. J.; Johnstone, C. A quantitative assessment of hERG liability as a function of lipophilicity Bioorg. Med. Chem. Lett. 2007, 17, 1759-1764
48. Denora, N.; Trapani, A.; Laquintana, V.; Lopedota, A.; Trapani, G. Recent advances in medicinal chemistry and pharmaceutical technology-strategies for drug delivery to the brain Curr. Top. Med. Chem. (Sharjah, United Arab Emirates) 2009, 9, 182-196
49. Alex, A.; Millan, D. S.; Perez, M.; Wakenhut, F.; Whitlock, G. A. Intramolecular hydrogen bonding to improve membrane permeability and absorption in beyond rule of five chemical space MedChemComm 2011, 2, 669-674
50. Kuhn, B.; Mohr, P.; Stahl, M. Intramolecular hydrogen bonding in medicinal chemistry J. Med. Chem. 2010, 53, 2601-2611
51. Patel, S.; Vuillard, L.; Cleasby, A.; Murray, C. W.; Yon, J. Apo and inhibitor complex structures of BACE (beta-secretase) J. Mol. Biol. 2004, 343, 407-416
52. Leslie, A. G. W. Recent changes to the MOSFLM package for processing film and image plate data Jt. CCP4 ESF-EAMCB Newsl. Protein Crystallogr. 1992, 26, 27
53. Evans, P. Scaling and assessment of data quality Acta Crystallogr., Sect. D: Biol. Crystallogr. 2006, D62, 72-82
54. Hong, L.; Koelsch, G.; Lin, X.; Wu, S.; Terzyan, S.; Ghosh, A. K.; Zhang, X. C.; Tang, J. Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor Science 2000, 290, 150-153
55. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr., Sect. D: Biol. Crystallogr. 1997, 53, 240-255
56. Emsley, P.; Cowtan, K. Coot: model-building tools for molecular graphics Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 2126-2132
57. BUSTER, version 2.11.1; Global Phasing Ltd.: Cambridge, U.K., 2010.
58. Wlodek, S.; Skillman, A. G.; Nicholls, A. Automated ligand placement and refinement with a combined force field and shape potential Acta Crystallogr., Sect. D: Biol. Crystallogr. 2006, 62, 741-749
59. LeDonne, N. C., Jr.; Rissolo, K.; Bulgarelli, J.; Tini, L. Use of structure-activity landscape index curves and curve integrals to evaluate the performance of multiple machine learning prediction models J. Cheminf. 2011, 3, 7
60. Friden, M.; Ljungqvist, H.; Middleton, B.; Bredberg, U.; Hammarlund-Udenaes, M. Improved measurement of drug exposure in the brain using drug-specific correction for residual blood J. Cereb. Blood Flow Metab. 2010, 30, 150-161
61. Borgegard, T.; Jureus, A.; Olsson, F.; Rosqvist, S.; Sabirsh, A.; Rotticci, D.; Paulsen, K.; Klintenberg, R.; Yan, H.; Waldman, M.; Stromberg, K.; Nord, J.; Johansson, J.; Regner, A.; Parpal, S.; Malinowsky, D.; Radesater, A. C.; Li, T.; Singh, R.; Eriksson, H.; Lundkvist, J. First and second generation gamma-secretase modulators (GSMs) modulate amyloid-beta (Abeta) peptide production through different mechanisms J. Biol. Chem. 2012, 287, 11810-11819
62. Dayneka, N. L.; Garg, V.; Jusko, W. J. Comparison of four basic models of indirect pharmacodynamic responses J. Pharmacokinet. Biopharm. 1993, 21, 457-478